{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:58:16Z","timestamp":1790812696282,"version":"4.1.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,21]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this viewpoint, we briefly review the status of antiretroviral therapy (ART), its unmet needs, and the role that broadly neutralizing antibodies (bNAbs) might have in the near future for the treatment of human immunodeficiency virus (HIV). We summarize advances in the development of bNAbs as antiretroviral therapy, the results of main clinical trials of bNAbs for HIV treatment and prevention, and its role in cure trials. The limitations of broadly neutralizing antibodies are the current need for primary resistance testing, the still unclear number of antibodies that must be combined, the lack of penetration in anatomical reservoirs, and the role they might play in cure studies. We compare the advantages and disadvantages of \u201cclassical ART\u201d and therapy based on broadly neutralizing antibodies. We conclude that broadly neutralizing antibodies still need considerable improvements before they can be considered an alternative to classical ART.<\/jats:p>","DOI":"10.1093\/cid\/ciac835","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T21:39:00Z","timestamp":1666906740000},"page":"1136-1141","source":"Crossref","is-referenced-by-count":11,"title":["Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in Reality"],"prefix":"10.1093","volume":"76","author":[{"given":"Laura","family":"Waters","sequence":"first","affiliation":[{"name":"Department of Sexual Health & HIV, Central & North West London NHS Trust , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"de Miguel-Buckley","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Department, La Paz University Hospital, IdiPAZ, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Poulin","sequence":"additional","affiliation":[{"name":"Centre int\u00e9gr\u00e9 de sant\u00e9 et de services sociaux des Laurentides, Clinique I.D. , Saint-J\u00e9r\u00f4me, Qu\u00e9bec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R","family":"Arribas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Department, La Paz University Hospital, IdiPAZ, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"2023032201025934800_"},{"key":"2023032201025934800_"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant HIV-1 infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N Engl J Med"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N Engl J Med"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0000000000002241","article-title":"Clinical and economic impact of ibalizumab for people with multidrug-resistant HIV in the United States","volume":"83","author":"Millham","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01876-21","article-title":"GSK3640254 is a novel HIV-1 maturation inhibitor with an optimized virology profile","volume":"66","author":"Dicker","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3018(21)00021-7","article-title":"Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial","volume":"8","author":"Molina","year":"2021","journal-title":"Lancet HIV"},{"key":"2023032201025934800_"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"Caskey","year":"2019","journal-title":"Nat Med"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/22221751.2020.1713707","article-title":"Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities","volume":"9","author":"Liu","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","article-title":"Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial","volume":"27","author":"Stephenson","year":"2021","journal-title":"Nat Med"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci Transl Med"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N Engl J Med"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat Med"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"710044","DOI":"10.3389\/fimmu.2021.710044","article-title":"Can broadly neutralizing HIV-1 antibodies help achieve an ART-free remission?","volume":"12","author":"Hsu","year":"2021","journal-title":"Front Immunol"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"708227","DOI":"10.3389\/fimmu.2021.708227","article-title":"To bnAb or not to bnAb: defining broadly neutralising antibodies against HIV-1","volume":"12","author":"Griffith","year":"2021","journal-title":"Front Immunol"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"101211","DOI":"10.1016\/j.coviro.2022.101211","article-title":"Broadly neutralizing antibodies against HIV-1 and concepts for application","volume":"54","author":"Gruell","year":"2022","journal-title":"Curr Opin Virol"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/COH.0000000000000731","article-title":"An exploration of how broadly neutralizing antibodies might induce HIV remission: the \u2018vaccinal\u2019 effect","volume":"17","author":"Tipoe","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010467","article-title":"HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys","volume":"18","author":"Moldt","year":"2022","journal-title":"PLoS Pathog"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-021-01651-9","article-title":"Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial","volume":"28","author":"Miller","year":"2022","journal-title":"Nat Med"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2666-5247(21)00239-1","article-title":"Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial","volume":"3","author":"Gruell","year":"2022","journal-title":"Lancet Microbe"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/infdis\/jiab487","article-title":"Stable latent HIV infection and low-level viremia despite treatment with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent vorinostat","volume":"225","author":"Gay","year":"2022","journal-title":"J Infect Dis"},{"key":"2023032201025934800_","author":"Gunst"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cell.2020.03.005","article-title":"Curing HIV: seeking to target and clear persistent infection","volume":"181","author":"Margolis","year":"2020","journal-title":"Cell"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13063-022-06151-w","article-title":"The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection\u2014study protocol for a two-stage randomised phase II trial","volume":"23","author":"Lee","year":"2022","journal-title":"Trials"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2020","journal-title":"Lancet"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV","volume":"385","author":"Paton","year":"2021","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"S861","DOI":"10.1093\/ofid\/ofz360.2162","article-title":"2484 Patient reported outcomes after switching to a 2-drug regimen of dolutegravir + rilpivirine: week 148 results from the sword-1 and sword-2 studies","volume":"6","author":"Oglesby","year":"2019","journal-title":"Open Forum Infectious Diseases"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40271-021-00524-0","article-title":"Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2M)","volume":"14","author":"Chounta","year":"2021","journal-title":"Patient"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/QAI.0000000000003033","article-title":"Safety and pharmacokinetics of intravenous 10-1074 and VRC01LS in young children","volume":"91","author":"Capparelli","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1016\/S2352-3018(22)00101-1","article-title":"Advancing the prevention and treatment of HIV in children: priorities for research and development","volume":"9","author":"Penazzato","year":"2022","journal-title":"Lancet HIV"},{"key":"2023032201025934800_"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/QAD.0000000000003143","article-title":"Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes","volume":"36","author":"Girometti","year":"2022","journal-title":"AIDS"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2023032201025934800_"},{"key":"2023032201025934800_","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009738","article-title":"Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques","volume":"17","author":"Wen","year":"2021","journal-title":"PLoS Pathog"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac835\/47260220\/ciac835.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/6\/1136\/49587521\/ciac835.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/6\/1136\/49587521\/ciac835.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T18:02:12Z","timestamp":1701280932000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/6\/1136\/6776109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,10,28]]},"published-print":{"date-parts":[[2023,3,21]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac835","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,15]]},"published":{"date-parts":[[2022,10,28]]}}}